GARP Research Maintains a 'Buy' on Conceptus (CPTS); Very Attractive Name in Health Care
CPTS Hot Sheet
Rating Summary:7 Buy, 6 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 20 | Down: 11 | New: 38
GARP Research maintains a 'Buy' on Conceptus (NASDAQ: CPTS).
GARP analyst, Alastair Mackay, said, "The judge in the recently-concluded patent-infringement trial declined to enjoin Adiana sales. In his decision, he went on to invalidate the jury’s award of a 20% royalty on Adiana. Thus, Hologic’s (Nasdaq: HOLX) device will continue to compete with Essure. GARP remains convinced that technical advantages favor the adoption of Essure, mostly at the expense of tubal ligations."
"We continue to believe that CPTS is one of the most attractive names in health care. Hysteroscopic sterilization should continue to take share from tubal ligation, given the benefits of HS for patients, physicians, and payers."
For an analyst ratings summary and ratings history on Conceptus click here. For more ratings news on Conceptus click here.
Shares of Conceptus closed at $11.89 yesterday, with a 52 week range of $9.68-$15.70.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
GARP analyst, Alastair Mackay, said, "The judge in the recently-concluded patent-infringement trial declined to enjoin Adiana sales. In his decision, he went on to invalidate the jury’s award of a 20% royalty on Adiana. Thus, Hologic’s (Nasdaq: HOLX) device will continue to compete with Essure. GARP remains convinced that technical advantages favor the adoption of Essure, mostly at the expense of tubal ligations."
"We continue to believe that CPTS is one of the most attractive names in health care. Hysteroscopic sterilization should continue to take share from tubal ligation, given the benefits of HS for patients, physicians, and payers."
For an analyst ratings summary and ratings history on Conceptus click here. For more ratings news on Conceptus click here.
Shares of Conceptus closed at $11.89 yesterday, with a 52 week range of $9.68-$15.70.
Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!
You May Also Be Interested In
- Barclays Cuts PT and Estimates on Dell (DELL); Apple's (AAPL) Momentum Proves Disrupting
- Deutsche Bank Cuts Price Target and EPS Estimates on J. C. Penney (JCP); There's Only Two Ways This Can Go
- Barclays Adjusting Estimates on Coca-Cola (KO); Seeing A More Well-Balanced Portfolio
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
